References
- Korompoki E, Gavriatopoulou M, Kontoyiannis DP. COVID-19 vaccines in patients with cancer – a welcome addition, but there is need for optimization. JAMA Oncol. 2021;7(8):1113–1114. doi:https://doi.org/10.1001/jamaoncol.2021.1218.
- Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi:https://doi.org/10.1016/S0140-6736(20)31173-9.
- Taghizadeh-Hesary F, Porouhan P, Soroosh D, PeyroShabany B, Shahidsales S, Keykhosravi B, et al. COVID-19 in cancer and non-cancer patients. Int J Cancer Manag. 2021;14(4):e110907. doi:https://doi.org/10.5812/ijcm.110907.
- Shahidsales S, Aledavood SA, Joudi M, Molaie F, Esmaily H, Javadinia SA. COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep (Hoboken). 2021;20:e1378. doi:https://doi.org/10.1002/cnr2.1378.
- Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies. Cancer. 2021;127(9):1459–1468. doi:https://doi.org/10.1002/cncr.33386.
- Kuderer NM, COVID-19 and Cancer Consortium, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. doi:https://doi.org/10.1016/s0140-6736(20)31187-9.
- Kregting LM, Kaljouw S, de Jonge L, Jansen EEL, Peterse EFP, Heijnsdijk EAM, et al. Effects of cancer screening restart strategies after COVID-19 disruption. Br J Cancer. 2021;124(9):1516–1523. doi:https://doi.org/10.1038/s41416-021-01261-9.
- Riera R, Bagattini ÂM, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. JCO Glob Oncol. 2021;7:311–323. doi:https://doi.org/10.1200/go.20.00639.
- Soroosh D, Javadinia SA. The COVID-19 outbreak and oncology centers in Iran. Int J Cancer Manag. 2020;13(6):e103283. doi:https://doi.org/10.5812/ijcm.103283.
- Kuderer NM, Hill JA, Carpenter PA, Lyman GH. Challenges and opportunities for COVID-19 vaccines in patients with cancer. Cancer Invest. 2021;39(3):205–213. doi:https://doi.org/10.1080/07357907.2021.1885596.
- Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:https://doi.org/10.1016/S1470-2045(20)30096-6.
- Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, et al. Multicenter study of the seroprevalence of antibodies against Covid-19 in patients with lymphoma: an analysis of the oncological group for the treatment and study of lymphomas (Gotel). Curr Oncol. 2021;28(2):1249–1255. doi:https://doi.org/10.3390/curroncol28020118.
- Liu T, COVID-19 in Cancer Patients Research Group, Zeng G, Tao H, Shi Y, Wang T, Liu T, et al. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer. 2020;147(11):3267–3269. doi:https://doi.org/10.1002/ijc.33148.
- Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine [database on the Internet]. World Health Organization. 2021. [cited August 25 2021]. Available from: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf.
- Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. Jama. 2021;326(1):35–45. doi:https://doi.org/10.1001/jama.2021.8565.
- Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:https://doi.org/10.1016/S1473-3099(20)30831-8.
- Li X-n, Huang Y, Wang W, Jing Q-l, Zhang C-h, Qin P-z, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10(1):1751–1732. doi:https://doi.org/10.1080/22221751.2021.1969291.
- Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22(5):581–583. doi:https://doi.org/10.1016/S1470-2045(21)00155-8.
- Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778. doi:https://doi.org/10.1016/S1470-2045(21)00213-8.
- Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv: Preprint Server Health Sci. 2021;2021.04.06.21254949. doi:https://doi.org/10.1101/2021.04.06.21254949.
- Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, et al. Antibody response to COVID-19 vaccination in adults with hematologic malignant disease. JAMA Oncol. 2021;e214381. doi:https://doi.org/10.1001/jamaoncol.2021.4381.
- Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133–1140. doi:https://doi.org/10.1001/jamaoncol.2021.2155.
- Yazaki S, Yoshida T, Kojima Y, Yagishita S, Nakahama H, Okinaka K, et al. Difference in SARS-CoV-2 antibody status between patients with cancer and health care workers during the COVID-19 pandemic in Japan. JAMA Oncol. 2021;77(8):1141–1148. doi:https://doi.org/10.1001/jamaoncol.2021.2159.